Search

Your search keyword '"Cosentino, Francesco"' showing total 9 results
Start Over Author "Cosentino, Francesco" Journal european journal of heart failure
9 results on '"Cosentino, Francesco"'

1. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

Author

Anker, Stefan D., primary, Usman, Muhammad Shariq, additional, Anker, Markus S., additional, Butler, Javed, additional, Böhm, Michael, additional, Abraham, William T., additional, Adamo, Marianna, additional, Chopra, Vijay K., additional, Cicoira, Mariantonietta, additional, Cosentino, Francesco, additional, Filippatos, Gerasimos, additional, Jankowska, Ewa A., additional, Lund, Lars H., additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Gonzalez‐Juanatey, Jose R., additional, Rakisheva, Amina, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Teerlink, John R., additional, Tschöpe, Carsten, additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, Zhang, Jian, additional, Zhang, Yuhui, additional, Bauersachs, Johann, additional, Landmesser, Ulf, additional, Zieroth, Shelley, additional, Tsioufis, Konstantinos, additional, Bayes‐Genis, Antoni, additional, Chioncel, Ovidiu, additional, Andreotti, Felicita, additional, Agabiti‐Rosei, Enrico, additional, Merino, Jose L., additional, Metra, Marco, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2023
Full Text
View/download PDF

2. Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors

Author

Herrington, William G., primary, Savarese, Gianluigi, additional, Haynes, Richard, additional, Marx, Nikolaus, additional, Mellbin, Linda, additional, Lund, Lars H., additional, Dendale, Paul, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Staplin, Natalie, additional, Baigent, Colin, additional, and Cosentino, Francesco, additional

Published
2021
Full Text
View/download PDF

3. Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry

Author

Becher, Peter M., primary, Schrage, Benedikt, additional, Ferrannini, Giulia, additional, Benson, Lina, additional, Butler, Javed, additional, Carrero, Juan Jesus, additional, Cosentino, Francesco, additional, Dahlström, Ulf, additional, Mellbin, Linda, additional, Rosano, Giuseppe M.C., additional, Sinagra, Gianfranco, additional, Stolfo, Davide, additional, Lund, Lars H., additional, and Savarese, Gianluigi, additional

Published
2021
Full Text
View/download PDF

4. Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure

Author

Seferović, Petar M., primary, Fragasso, Gabriele, additional, Petrie, Mark, additional, Mullens, Wilfried, additional, Ferrari, Roberto, additional, Thum, Thomas, additional, Bauersachs, Johann, additional, Anker, Stefan D., additional, Ray, Robin, additional, Çavuşoğlu, Yuksel, additional, Polovina, Marija, additional, Metra, Marco, additional, Ambrosio, Giuseppe, additional, Prasad, Krishna, additional, Seferović, Jelena, additional, Jhund, Pardeep S., additional, Dattilo, Giuseppe, additional, Čelutkiene, Jelena, additional, Piepoli, Massimo, additional, Moura, Brenda, additional, Chioncel, Ovidiu, additional, Ben Gal, Tuvia, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Hill, Loreena, additional, Lopatin, Yuri, additional, Lyon, Alexander R., additional, Ponikowski, Piotr, additional, Lainščak, Mitja, additional, Jankowska, Ewa, additional, Mueller, Christian, additional, Cosentino, Francesco, additional, Lund, Lars H., additional, Filippatos, Gerasimos S., additional, Ruschitzka, Frank, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2020
Full Text
View/download PDF

5. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Petar M., primary, Fragasso, Gabriele, additional, Petrie, Mark, additional, Mullens, Wilfried, additional, Ferrari, Roberto, additional, Thum, Thomas, additional, Bauersachs, Johann, additional, Anker, Stefan D., additional, Ray, Robin, additional, Çavuşoğlu, Yuksel, additional, Polovina, Marija, additional, Metra, Marco, additional, Ambrosio, Giuseppe, additional, Prasad, Krishna, additional, Seferović, Jelena, additional, Jhund, Pardeep S., additional, Dattilo, Giuseppe, additional, Čelutkiene, Jelena, additional, Piepoli, Massimo, additional, Moura, Brenda, additional, Chioncel, Ovidiu, additional, Ben Gal, Tuvia, additional, Heymans, Stefan, additional, Boer, Rudolf A., additional, Jaarsma, Tiny, additional, Hill, Loreena, additional, Lopatin, Yuri, additional, Lyon, Alexander R., additional, Ponikowski, Piotr, additional, Lainščak, Mitja, additional, Jankowska, Ewa, additional, Mueller, Christian, additional, Cosentino, Francesco, additional, Lund, Lars, additional, Filippatos, Gerasimos S., additional, Ruschitzka, Frank, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2020
Full Text
View/download PDF

6. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure

Author

Seferović, Petar M., primary, Coats, Andrew J.S., additional, Ponikowski, Piotr, additional, Filippatos, Gerasimos, additional, Huelsmann, Martin, additional, Jhund, Pardeep S., additional, Polovina, Marija M., additional, Komajda, Michel, additional, Seferović, Jelena, additional, Sari, Ibrahim, additional, Cosentino, Francesco, additional, Ambrosio, Giuseppe, additional, Metra, Marco, additional, Piepoli, Massimo, additional, Chioncel, Ovidiu, additional, Lund, Lars H., additional, Thum, Thomas, additional, De Boer, Rudolf A., additional, Mullens, Wilfried, additional, Lopatin, Yuri, additional, Volterrani, Maurizio, additional, Hill, Loreena, additional, Bauersachs, Johann, additional, Lyon, Alexander, additional, Petrie, Mark C., additional, Anker, Stefan, additional, and Rosano, Giuseppe M.C., additional

Published
2020
Full Text
View/download PDF

7. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Petar M., primary, Petrie, Mark C., additional, Filippatos, Gerasimos S., additional, Anker, Stefan D., additional, Rosano, Giuseppe, additional, Bauersachs, Johann, additional, Paulus, Walter J., additional, Komajda, Michel, additional, Cosentino, Francesco, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Doehner, Wolfram, additional, Lambrinou, Ekaterini, additional, Lopatin, Yuri, additional, Piepoli, Massimo F., additional, Theodorakis, Michael J., additional, Wiggers, Henrik, additional, Lekakis, John, additional, Mebazaa, Alexandre, additional, Mamas, Mamas A., additional, Tschöpe, Carsten, additional, Hoes, Arno W., additional, Seferović, Jelena P., additional, Logue, Jennifer, additional, McDonagh, Theresa, additional, Riley, Jillian P., additional, Milinković, Ivan, additional, Polovina, Marija, additional, van Veldhuisen, Dirk J., additional, Lainscak, Mitja, additional, Maggioni, Aldo P., additional, Ruschitzka, Frank, additional, and McMurray, John J.V., additional

Published
2018
Full Text
View/download PDF

8. Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.

Author

Pandey A, Kolkailah AA, McGuire DK, Frederich RC, Cater NB, Cosentino F, Pratley RE, Dagogo-Jack S, Cherney DZI, Wynant W, Gantz I, Mancuso JP, Masiukiewicz U, and Cannon CP

Abstract

Aims: In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease. We evaluated the impact of ertugliflozin on the broader spectrum of all reported heart failure (HF) events independent of adjudication confirmation., Methods and Results: Data from participants who received ertugliflozin (5 or 15 mg) were pooled and compared versus placebo. HF events included all investigator-reported HF adverse events (AEs) and serious AEs (SAEs) based on the narrow standardized Medical Dictionary for Regulatory Activities (MedDRA) query 'cardiac failure'. Terms for orthopnoea, dyspnoea, and peripheral oedema were evaluated separately. The effect of ertugliflozin on the first HF event was assessed by Cox proportional hazard models. Total HF events were assessed by Andersen-Gill models to account for first and recurrent events. A total of 8238 participants received ≥1 dose of ertugliflozin or placebo (mean follow-up 3.5 years). Investigator-reported HF events and AE capture yielded 420 first and 627 total HF events (vs. 238 and 345 adjudication-confirmed HHF events, respectively, in the primary analyses). Ertugliflozin reduced the risk for first (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.57-0.84; p < 0.001) and total HF AEs (HR 0.66; 95% CI 0.57-0.78; p < 0.001), with similar results for first and total HF SAEs. Additionally, ertugliflozin reduced oedema risk, but not orthopnoea/dyspnoea., Conclusion: The effect of ertugliflozin was consistent across the spectrum of total investigator-reported HF AEs and was similar in magnitude to adjudicated HHF events., (© 2025 Merck & Co Inc. Pfizer Inc and The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2025
Full Text
View/download PDF

9. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases.

Author

Seferović PM, Paulus WJ, Rosano G, Polovina M, Petrie MC, Jhund PS, Tschöpe C, Sattar N, Piepoli M, Papp Z, Standl E, Mamas MA, Valensi P, Linhart A, Lalić N, Ceriello A, Döhner W, Ristić A, Milinković I, Seferović J, Cosentino F, Metra M, and Coats AJS

Subjects
Humans, Societies, Medical, Diabetes Mellitus, Type 2 complications, Diabetic Cardiomyopathies diagnosis, Diabetic Cardiomyopathies physiopathology, Heart Failure diagnosis, Heart Failure etiology, Heart Failure physiopathology
Abstract

The association between type 2 diabetes mellitus (T2DM) and heart failure (HF) has been firmly established; however, the entity of diabetic myocardial disorder (previously called diabetic cardiomyopathy) remains a matter of debate. Diabetic myocardial disorder was originally described as the occurrence of myocardial structural/functional abnormalities associated with T2DM in the absence of coronary heart disease, hypertension and/or obesity. However, supporting evidence has been derived from experimental and small clinical studies. Only a minority of T2DM patients are recognized as having this condition in the absence of contributing factors, thereby limiting its clinical utility. Therefore, this concept is increasingly being viewed along the evolving HF trajectory, where patients with T2DM and asymptomatic structural/functional cardiac abnormalities could be considered as having pre-HF. The importance of recognizing this stage has gained interest due to the potential for current treatments to halt or delay the progression to overt HF in some patients. This document is an expert consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. It summarizes contemporary understanding of the association between T2DM and HF and discuses current knowledge and uncertainties about diabetic myocardial disorder that deserve future research. It also proposes a new definition, whereby diabetic myocardial disorder is defined as systolic and/or diastolic myocardial dysfunction in the presence of diabetes. Diabetes is rarely exclusively responsible for myocardial dysfunction, but usually acts in association with obesity, arterial hypertension, chronic kidney disease and/or coronary artery disease, causing additive myocardial impairment., (© 2024 European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results